908 Devices Inc. (NASDAQ:MASS) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• 908 Devices Inc. has a consensus rating of "Moderate Buy" from analysts, with one sell rating and three buy ratings from five covering research firms.
• The company's market capitalization is $297.64 million and it recently reported a quarterly loss of ($0.18) earnings per share, missing estimates by $0.02.
• Insider selling activity has been observed, with CFO Joseph H. Iv Griffith selling 5,000 shares at an average price of $7.07, contributing to a 4.86% decrease in ownership.

908 Devices Inc. (NASDAQ:MASS - Get Free Report) has earned a consensus rating of "Moderate Buy" from the five research firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $8.00.

A number of brokerages have recently weighed in on MASS. Wall Street Zen raised shares of 908 Devices from a "sell" rating to a "hold" rating in a research note on Monday, September 15th. Leerink Partners upgraded shares of 908 Devices from a "market perform" rating to an "outperform" rating and set a $12.00 target price on the stock in a report on Tuesday, August 5th. Leerink Partnrs upgraded shares of 908 Devices from a "hold" rating to a "strong-buy" rating in a report on Tuesday, August 5th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of 908 Devices in a research report on Wednesday, October 8th.

908 Devices Trading Down 5.4%

Shares of 908 Devices stock opened at $8.30 on Thursday. The company has a 50-day moving average of $7.20 and a two-hundred day moving average of $6.42. 908 Devices has a 12-month low of $1.81 and a 12-month high of $9.34. The stock has a market cap of $297.64 million, a PE ratio of -15.37 and a beta of 0.46.

908 Devices (NASDAQ:MASS - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.02). The firm had revenue of $4.70 million during the quarter, compared to analyst estimates of $12.17 million. 908 Devices had a negative return on equity of 24.30% and a negative net margin of 30.54%. 908 Devices has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that 908 Devices will post -1.99 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Joseph H. Iv Griffith sold 5,000 shares of the stock in a transaction dated Friday, September 19th. The stock was sold at an average price of $7.07, for a total transaction of $35,350.00. Following the transaction, the chief financial officer directly owned 97,930 shares in the company, valued at approximately $692,365.10. This represents a 4.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders sold 10,000 shares of company stock valued at $80,593 in the last ninety days. Corporate insiders own 23.70% of the company's stock.

Institutional Investors Weigh In On 908 Devices

Several hedge funds have recently modified their holdings of the stock. Farther Finance Advisors LLC purchased a new position in shares of 908 Devices in the 3rd quarter worth $28,000. Nisa Investment Advisors LLC increased its stake in 908 Devices by 453.2% during the second quarter. Nisa Investment Advisors LLC now owns 3,784 shares of the company's stock worth $27,000 after acquiring an additional 3,100 shares during the last quarter. ANTIPODES PARTNERS Ltd increased its position in 908 Devices by 49.7% during the 2nd quarter. ANTIPODES PARTNERS Ltd now owns 6,558 shares of the company's stock worth $47,000 after purchasing an additional 2,176 shares in the last quarter. Raymond James Financial Inc. purchased a new position in 908 Devices in the second quarter valued at approximately $48,000. Finally, CWM LLC lifted its position in 908 Devices by 541.2% during the first quarter. CWM LLC now owns 6,963 shares of the company's stock valued at $31,000 after buying an additional 5,877 shares in the last quarter. 88.06% of the stock is owned by institutional investors and hedge funds.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.